Journal of Clinical Oncology
Articles in this Issue
Initial phase 1b/2 study results of purinostat mesylate (PM) in combination with pomalidomide (POM) and low dexamethasone (DEX) in patients with RRMM.
TPS7581 Background: MM remains an incurable disease and resistance mechanisms are emerging. PM is a high selective HDAC I/...
Use of palliative radiation and association with end-of-life quality metrics and healthcare utilization for patients with gynecologic malignancies in Ontario, Canada from 2006-2018.
e24055 Background: The optimal use of radiotherapy at the end of life (EOL) is undefined in gynecologic oncology. We inves...
Population-based breast cancer incidence by age, sex, subtype, and stage.
e22620 Background: Granular estimates of breast cancer incidence by age, sex, molecular subtype, and stage are essential f...
Demographic and regional trends in combined colorectal cancer and cerebrovascular disease-related mortality in the United States (1999–2023).
e15715 Background: Prior studies suggest substantial cerebrovascular disease (CVD) comorbidity among patients with colorec...
Allele-specific targeting of CD33 as a novel approach to enhance CAR-T selectivity in relapsed acute myeloid leukemia post–allogeneic transplantation.
6554 Background: Relapse after allogeneic hematopoietic cell transplant (HCT) represents the most common treatment failure...
Association of SARS-CoV-2 vaccination with survival outcomes in patients with metastatic solid tumors treated with immune checkpoint inhibitors.
2591 Background: Patients with cancer experience disproportionately high morbidity and mortality from SARS-CoV-2 infection...
Assessing burden and outcomes: Colon cancer survival across the U.S. safety-net spectrum.
11176 Background: Safety-net hospitals (SNHs) provide essential care for uninsured and underinsured patients but often fac...
Social deprivation index (SDI) as a predictor of racial and ethnic disparity in a large real world cancer database.
e23429 Background: Healthcare access and representation can vary significantly by race, ethnicity and neighborhood depriva...
Convenience vs. complexity: Adoption of subcutaneous PD-(L)1s in lung cancer in EU4+UK.
3083 Background: Subcutaneous (SC) PD-(L)1 formulations represent a significant step towards simplifying treatment adminis...
New oral SERD plus CDK4/6 inhibitors in recurrent or metastatic ER+/HER2- breast cancer: A systematic review and single-arm meta-analysis.
e13072 Background: Hormone-positive breast cancer is prone to late recurrence and is biologically heterogeneous. The adven...
Association of carbon tetrachloride with lung cancer incidence and mortality, including effects in low-smoking regions.
8076 Background: Although cigarette smoking is the main risk factor for lung cancer, 10–20 percent of cases occur in non-s...
Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis.
6035 Background: Aggressive systemic cancer treatment near the end of life (EOL) rarely benefits patients and is an establ...
Characterization of contemporary practice patterns in the management of <i>IDH</i> -mutant glioma: A multidisciplinary multi-institutional survey.
2058 Background: The management of isocitrate dehydrogenase (IDH) mutant glioma is rapidly evolving following the recent F...
Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.
2661 Background: CRD3874-SI is a first in class, systemically administered, allosteric STING agonist that blocks STING’s p...
Assessing grade 3 and grade 4 immunotherapy-induced dermatologic toxicities at a tertiary medical center.
e24192 Background: Immune checkpoint inhibitors (ICIs) are increasingly used across multiple malignancies but are associat...
Development of a composite risk score for chemotherapy toxicity and unplanned hospitalization in older adults with cancer: A prospective cohort study.
1659 Background: Older adults receiving chemotherapy are at high risk for severe treatment-related toxicities, which may c...
HPV-enriched oropharyngeal head and neck cancer and inpatient outcomes: A national analysis of U.S. hospitalizations, 2016 to 2023.
e23173 Background: HPV-associated oropharyngeal cancer has favorable oncologic prognosis, but its inpatient risk profile i...
Chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with T follicular helper phenotype: Results of the phase II SWIFT trial.
7082 Background: Peripheral T-Cell Lymphoma with T-follicular helper phenotype (PTCL-TFH), which mainly includes angioimmu...
Spatial immune architecture as used to define progression and treatment response in penile squamous cell carcinoma.
5035 Background: Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy with limited treatment options and...
Access-related disparities and survival in high-grade glioma: A social vulnerability analysis at a Texas tertiary cancer center.
e14043 Background: Glioblastoma (GBM) and astrocytoma, IDH-mutant grade 4, are aggressive brain tumors requiring timely ac...
A phase 3 study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard-of-care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress.
TPS8672 Background: Despite progress in the treatment of advanced non-small cell lung cancer (NSCLC), therapeutic options...
Proton pump inhibitor use and overall survival in patients with gastric adenocarcinoma treated with first-line immunotherapy: A real-world pharmacoepidemiologic study.
e15693 Background: Proton pump inhibitors (PPIs) are frequently prescribed to patients with gastric cancer for gastroesoph...
Liquid biopsy with peripheral blood mononuclear cells: Deciphering systemic immunity to predict PARPi-immunotherapy efficacy in early HER2-negative breast cancer.
e14531 Background: Neoadjuvant immunotherapy shows promising efficacy in early HER2-negative breast cancer, predictive bio...
A phase Ib/II study of mirdametinib in combination with palbociclib in patients with advanced dedifferentiated liposarcoma.
TPS11594 Background: Dedifferentiated liposarcoma (DDLPS) is a rare adipocytic malignancy characterized by frequent amplif...
Genomic landscape of <i>TP53</i> Y220C–mutated clinically advanced prostate carcinoma (CAPC).
5044 Background: The TP53 Y220C base substitution mutation has become a significan...